Welireg approved in US for rare VHL-associated cancers
VHL is a rare genetic disease which puts patients at risk of developing benign blood vessel tumours and several cancers
Read More
Tag: von Hippel-Lindau disease
Priority review for Merck & Co’s belzutifan in rare kidney cancer subset
Belzutifan is a potential treatment for von Hippel-Lindau disease-associated renal cell carcinoma
Read More
